和血明目片联合雷珠单抗治疗湿性年龄相关性黄斑变性的临床效果

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (751 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical efficacy of Hexue Mingmu tablets combined with anti-vascular endothelial growth factor (VEGF) drug (ranibizumab) in the treatment of wet age-related macular degeneration (wAMD).Methods Ninety-six patients (96 eyes) with wAMD were randomly divided into two groups using the random number table method: the treatment group (48 eyes)that was treated with anti- VEGF intravitreal injection combined with Hexue Mingmu tablets and the control group(48 eyes) treated with anti-VEGF intravitreal injection alone. Both groups were treated for three consecutive months. The best corrected visual acuity (BCVA), central retinal thickness in the macular area (CRT), macular hemorrhage area, exudation area and cumulative injury area were observed in both groups for 3 months. The recurrence of macular edema was analyzed and evaluated statistically after the follow-up.Results (1)After 3 months of treatment, BCVA was increased in both groups(t=8.320 vs t=4.689),especially in the treatment group. After 6 months of treatment, BCVA was increased in both groups (t=7.909 vs t=3.808) and the difference between the two groups was statistically significant.(2)After 3 months of treatment, CRT was decreased in both groups(t=16.864 vs t=14.175), but there was no statistically significant difference between the two groups. After 6 months of treatment, CRT was decreased in both groups, especially in the treatment group, but there was statistically significant difference between the two groups.(3) After 3 months of treatment, the areas of macular hemorrhage, exudation and cumulative injury in both groups were significantly smaller, especially in the treatment group (P<0.05). (4) The recurrence rate was significantly different between the two groups (χ²=4.937,P<0.05).Conclusions The clinical efficacy of anti-VEGF intravitreal injection combined with Hexue Mingmu tablets in the treatment of age-related macular degeneration is confirmed, and the combined treatment is superior to the single anti-VEGF intravitreal injection in the control of macular hemorrhage and edema recurrence.

Key words： Hexue Mingmu tablet age-related macular degeneration anti-VEGF

Received: 20 May 2019

ZTFLH:

R276.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Chao
	YANG Yongsheng

Cite this article:

XU Chao,YANG Yongsheng. Clinical effect of Hexue Mingmu pills combined with ranibizumab in treating wet age-related macular degeneration[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(11): 956-959.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2019/V30/I11/956

[1]	Pedrosa A C, Reis S A, Pinheiro C J, et al. Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes[J]. Clin Ophthalmol,2016,29(10):541-546.
[2]	黎晓新.眼内抗血管生成药物临床应用的利与弊[J].中华眼科杂志,2012,48(10):870-873.
[3]	罗丹. 黄斑变性1号方治疗渗出型年龄相关性黄斑变性的临床观察及机制研究[D].北京:北京中医药大学,2017.
[4]	唐由之,周尚昆,冯俊,等.中药治疗湿性晚期老年性黄斑变性临床疗效观察[J].中国中医眼科杂志, 2009,19(6): 340-341.
[5]	廖良,韦企平.和血明目片参与治疗眼底出血性疾病的系统评价[J].湖南中医药大学学报2010,30(2):65-67.
[6]	中华医学会眼科学会眼底病学组.老年性黄斑变性的临床诊断标准.眼底病[J].中华眼科杂志,1987(3):封二.
[7]	李文博,陈松.老年性黄斑变性发病机制的研究进展[J].中华眼底病杂志,2006,22(4):283-285.
[8]	俞德超,张明.渗出型老年性黄斑变性治疗药物的研究进展[J].中华眼底病杂志,2010,26(1):88-91.
[9]	杨雪琦,姜英梅,韩峰,等.和血明目片治疗大量玻璃体积血的临床疗效观察[J].中医临床研究, 2017,9(29):130-132.
[10]	周黎纹.和血明目片在糖尿病视网膜病变性眼底出血治疗中的有效运用[J].中国现代药物应用,2018,12(7):90-92.
[11]	刘洪安,李若溪.和血明目片治疗视网膜静脉阻塞性眼底出血的临床疗效[J].中国药物经济学,2018,13(7):80-82.
[12]	李沛,徐杰.和血明目片治疗高血压眼底出血的临床观察[J].中国民间疗法,2018,26(5):26.